瑞普生物(300119.SZ):員工持股計劃存續期即將屆滿
格隆匯2月21日丨瑞普生物(300119.SZ)公佈,鑑於公司員工持股計劃存續期將於2020年8月23日屆滿,2016年7月8日,中國證監會下發“證監許可[2016]1328號”《關於核准天津瑞普生物技術股份有限公司非公開發行股票的批覆》,核准公司非公開發行股票事項。公司員工持股計劃通過“中信證券-瑞普生物投資1號定向資產管理計劃”認購上市公司非公開發行股票約479.09萬股(佔公司總股本的1.18%)。上述股份於2016年8月23日完成發行上市。根據《天津瑞普生物技術股份有限公司員工持股計劃(草案第二次修訂稿)》等有關規定,公司此次員工持股計劃存續期為48個月(其中鎖定期為36個月,解鎖期為12個月),自公司非公開發行的股票登記至員工持股計劃名下時起算。
截止公告披露日,公司此次員工持股計劃已經全部解鎖完畢,尚未出售任何股票,未出現用於抵押、質押、擔保、償還債務等情形,未出現任一持有人持有的此次員工持股計劃份額所對應的公司股票數量超過公司股本總額1%的情形,未出現此次員工持股計劃持有人之外的第三人對員工持股計劃的股票和資金提出權利主張的情形。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.